The primary purpose of any Expanded Access (EAP) or Post-Trial Access (PTA) Program is to help patients with serious or life-threatening conditions gain access to potentially life-saving therapies when no suitable treatment options are available. The patients and physicians requesting expanded access use of an investigational product are often navigating urgent and difficult circumstances. Sponsors, meanwhile, must balance compassionate access with regulatory obligations, product availability, safety oversight, and broader clinical development priorities. A well-designed access program brings these considerations together in a controlled, ethical, and compliant way, while keeping patient wellbeing at the centre of every decision.
When implementing an EAP or PTA program, it is essential for Sponsors to select a partner with an experienced and knowledgeable regulatory team who can provide strategic guidance throughout the program lifecycle. Strong regulatory partners help Sponsors interpret complex regulations, anticipate challenges, align key stakeholders, and manage evolving program requirements.
Understanding the Regulatory Landscape
Behind every EAP is a regulatory pathway – or more often than not, a number of regulatory pathways – that need to be understood, interpreted, and carefully managed. For Sponsors, this means looking beyond the desire to provide access and considering how that access can be delivered responsibly, consistently, and in line with applicable requirements. This involves practical questions around country-specific expectations, documentation requirements, stakeholder responsibilities, safety considerations, and decisions that can have meaningful implications for patients, physicians, and Sponsor teams.
It is important to note that there is no single global framework governing expanded access. Each major regulatory authority – including the FDA in the United States, the EMA and individual national competent authorities across Europe, PMDA in Japan, and Health Canada, among others – has developed its own pathway structures, terminology, and submission requirements. What is classified as “compassionate use” in one jurisdiction may be referred to as a “named patient program” or “medical need program” in another, and the procedural requirements can differ substantially, even where the underlying intent is the same. For Sponsors operating across multiple markets, this fragmentation means that a single access program may simultaneously adhere to several distinct regulatory frameworks, each with its own expectations around approval timelines, safety reporting, and Sponsor obligations.
To add to this complexity, the regulatory landscape is not static. Regulatory guidance around expanded access continues to evolve, with authorities periodically updating their frameworks or guidance documents in response to scientific developments, patient advocacy, and lessons learned from prior programs. Requirements that applied to a program several years ago may no longer reflect current expectations, and new guidance can emerge during the lifecycle of an active program. This dynamic environment makes it essential to work with a regulatory partner who not only understands the current state of each market but actively monitors changes and can advise Sponsors when updated approaches or revised submissions may be required.
Why Regulatory Intelligence Matters
Understanding the regulatory landscape is the starting point, but it is not the whole picture. Regulatory expertise alone is often not sufficient to support effective access planning. Sponsors also benefit from access to current regulatory intelligence that helps them understand how evolving requirements are being interpreted and applied in practice. While published regulations provide the framework, regulatory intelligence provides insight into emerging authority expectations, changes in guidance, evolving post-trial access requirements, charging considerations, and country-specific nuances.
This distinction matters: two Sponsors working from the same published guidance can reach very different outcomes depending on whether their partner understands how that guidance is currently being applied by reviewers and authorities on the ground. A regulatory partner with a dedicated regulatory intelligence capability can help Sponsors anticipate change before it disrupts an active program, assess the potential impact of emerging developments on program design or timelines, and make more informed decisions throughout the program lifecycle. In this way, rather than reacting to changes after they take effect, Sponsors are able to plan ahead of them.
Helping Sponsors Make Informed Decisions
Because expanded access often involves unfamiliar and heterogeneous pathways, evolving country requirements, and complex decision-making across multiple markets, Sponsors benefit most when their EAP partner not only provides regulatory answers, but also helps to develop a holistic regulatory strategy by clearly defining available options, assessing associated risks and opportunities and explaining the implications of key decisions across countries and stakeholders. In practice, this means helping Sponsors work through a number of interconnected regulatory and strategic considerations before access is opened.
Below we highlight some of the most common question and explore how they are typically addressed:
Is expanded access appropriate at a particular stage of development?
Determining whether expanded access is appropriate is not simply a question of development phase. It requires a broader assessment of the available evidence, the intended patient population, the level of unmet need, and the Sponsor’s ability to support access responsibly. A strong regulatory partner can help Sponsors evaluate these considerations objectively. This includes reviewing whether the proposed patient population aligns with the evidence generated to date, whether the treating physician has enough information to make an informed decision, and whether the access route being considered is proportionate to the level of data available. The aim is to ensure that expanded access is not introduced too early, too broadly, or in a way that could create unnecessary risk for patients or complications for the development program.
How could an access program affect ongoing or future clinical trials and commercialization plans?
An EAP or PTA program can support patient access, but it should be designed in a way that protects the integrity of the Sponsor’s broader development and commercialization strategy. If not carefully managed, an access program may influence clinical trial recruitment, create expectations in markets where approval or reimbursement is still uncertain, or place pressure on supply that was originally allocated for clinical development. These considerations are particularly important in rare diseases, oncology, and other areas where eligible patient populations may be limited. It is important to map these implications before launch, ensuring that the program supports patient access without creating avoidable operational, regulatory, or strategic challenges later.
What are the implications of initiating expanded access or post-trial access in a specific country?
The implications of initiating post-trial access or expanded access can vary significantly by country, particularly in relation to supply duration, cost recovery, and the transition from pre-approval access to commercial availability. In some markets, once access is initiated, Sponsors may be expected to continue supplying treatment until marketing authorization is granted and, in certain cases, beyond approval while pricing and reimbursement decisions are still pending. This can create a longer-term commitment than initially anticipated, especially where patients have already started treatment and there is no appropriate alternative available. This may also influence launch sequencing, reimbursement strategy, local stakeholder engagement, and internal decisions around whether and when to pursue marketing authorization in that market. Sponsors should therefore assess each country carefully with their vendor before opening access. These assessments should consider not only the available regulatory pathway, but also broader factors such as treatment commitments, commercialisation plans, reimbursement timelines, stakeholder responsibilities, supply implications, and potential exit strategies that may influence long-term program feasibility.
How should safety responsibilities be managed across countries? E.g. HCP-led vs Sponsor submission requirements.
Pharmacovigilance obligations exist in every pathway, but the focus of responsibility shifts with the route. In many countries, under individual, physician-led access, the treating physician carries substantial responsibility for adverse-event reporting, whereas under Sponsor-initiated cohort programs the Sponsor typically assumes protocol-defined safety monitoring and reporting duties. In cross-border programs the practical task is reconciling differing national reporting timelines and formats into a single coherent safety system, with clearly documented hand-offs between physician, Sponsor, and any vendor. Defining these responsibilities explicitly at the outset is what prevents reporting gaps later. Effective implementation also requires clear alignment between Regulatory Affairs, Pharmacovigilance, Operations, Sponsors, and treating physicians to ensure responsibilities are understood and managed consistently across jurisdictions.
How should demand be managed when product supply is limited?
When supply is limited, demand management needs to be handled through clear, consistent, and ethically defensible criteria. Eligibility criteria should be defined in advance and applied consistently across markets, taking into account medical need, available clinical evidence, benefit-risk considerations, and whether the patient has access to an ongoing clinical trial or other appropriate treatment option. A structured intake and review process is essential. This may include centralizing physician requests, documenting the rationale for approvals and declines, and aligning internal stakeholders on how supply will be allocated. Communication is also important, particularly where requests cannot be supported. A strong regulatory partner can help Sponsors establish a transparent decision-making framework that balances compassion for individual patients with responsible stewardship of limited investigational product supply.
Why the Right Regulatory Partner Matters
Ultimately, EAP and PTA programs require more than a pathway to supply. They require careful regulatory interpretation, strategic planning, clear governance, and practical decision-making across countries, stakeholders, and program stages. Experienced regulatory partners help Sponsors assess feasibility, navigate country-specific obligations, develops tailored regulatory strategies and adapt to the evolving requirement throughout the lifecycle of the asset. When these elements are aligned early, access can be delivered in a way that is responsible, compliant, and centered on the patients who need it most.
At WEP Clinical, we believe that effective Sponsor–Vendor relationships are built on transparency, responsiveness, and shared accountability. our approach is to support Sponsors by connecting regulatory understanding with practical program delivery. Our regulatory experts help Sponsors navigate complex requirements, asses country-specific opportunities and risks and understand the implications of key program decisions. We believe that when regulatory guidance is clear, practical, and well communicated, Sponsors are better positioned to move forward responsibly. And in expanded access, that clarity can make all the difference.
